News
14h
Clinical Trials Arena on MSNLumiThera shows improved AMD trial resultsThe extension trial findings for LumiThera’s Valeda dry AMD treatment suggest longer treatment and earlier intervention ...
4mon
The Brighterside of News on MSNNew eye drops successfully treat age-related macular degenerationAge-related macular degeneration (AMD) is a leading cause of vision loss among individuals over 65. While the dry form of AMD ...
Geographic atrophy is an advanced form of dry age-related macular degeneration ... including new medications and promising future therapies. What is the new treatment for geographic atrophy?
Both eyes had already been treated for dry macular degeneration, a more common form ... of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet ...
Dry age-related macular degeneration (AMD ... pegcetacoplan showed a statistically significant reduction of new scotomatous points on microperimetry, which was a prespecified secondary endpoint.
New clearance has extended the range of uses for the device to include dry-AMD. OT found out more at 100% Optical ...
Do you have questions about treatment of age-related macular degeneration, otherwise known as dry AMD? Anjali Rajesh Shah ... Rajesh Shah: There are two new medications: one, pegcetacoplan; Synfovre, ...
The 2024 American Academy of Ophthalmology (AAO) Preferred Practice Patterns provide guidance for physicians about best practices in the treatment of age-related macular degeneration (AMD).
Now, new research from the University ... For patients with dry macular degeneration, the most common form of the disease, treatment includes injecting antibodies directly into the eye.
In the last 20 years, there have been rapid advances in the treatment options ... patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...
Slowed fibrosis progression comparable to that achieved with GLP-1/GIP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and ...
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results